Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 20/20 | 0.53 |
| ▸ | HTR1A | P08908 | 17/20 | 0.53 |
| ▸ | HTR2A | P28223 | 17/20 | 0.53 |
| ▸ | DRD1 | P21728 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | DRD5 | P21918 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL251847 | 0.92 | DRD2 (0.56) | DRD2HTR1AHTR2ADRD1DRD4 | |
| SCHEMBL5217914 | 0.84 | DRD2 (0.50) | DRD2HTR1AHTR2ADRD1DRD4 | |
| SCHEMBL16559741 | 0.82 | DRD2 (0.67) | DRD2HTR1AHTR2ADRD1DRD4 | |
| SCHEMBL5249304 | 0.81 | DRD2 (0.41) | DRD2HTR1AHTR2ADRD1DRD4 | |
| SCHEMBL3419422 | 0.80 | DRD2 (0.57) | DRD2HTR1AHTR2ADRD1DRD4 | |
| SCHEMBL5370847 | 0.80 | DRD2 (0.60) | DRD2HTR1AHTR2ADRD1DRD4 | |
| SCHEMBL20078469 | 0.79 | DRD2 (0.48) | DRD2HTR1AHTR2A | |
| SCHEMBL14984327 | 0.79 | DRD2 (0.58) | DRD2HTR1AHTR2A | |
| SCHEMBL5220878 | 0.79 | DRD2 (0.49) | DRD2HTR1AHTR2ADRD1DRD4 | |
| SCHEMBL16559687 | 0.77 | DRD2 (0.63) | DRD2HTR1AHTR2ADRD1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1869041-A1 | TETRAHYDRO-PYRIDOAZEPIN-8-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | Warner-Lambert Company LLC (US) | 2007-12-26 | — | — | EP | disclosed |
| US-20060234997-A1 | Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia | WARNER-LAMBERT COMPANY LLC | 2006-10-19 | — | — | US | disclosed |
| WO-2006103559-A1 | TETRAHYDRO-PYRIDOAZEPIN-8-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC (US) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060234997-A1 | Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia | PTGDR, GRIN2A, PTGDR2 | DRD2 8/4885HTR1A 36/4885HTR2A 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.